Valuation: Autolus Therapeutics plc

Market Cap 351M 317M 293M 264M 500M 32.95B 513M 3.51B 1.4B 17.65B 1.32B 1.29B 56.16B P/E 2026 *
-1.64x
P/E 2027 * -1.9x
Enterprise Value 199M 179M 166M 150M 283M 18.66B 290M 1.99B 791M 9.99B 747M 731M 31.81B EV / Sales 2026 *
1.32x
EV / Sales 2027 * 1.43x
Free-Float
-
Yield 2026 *
-
Yield 2027 * -
1 day-4.92%
1 week-9.06%
Current month-17.43%
1 month-27.87%
3 months-46.14%
6 months-20.57%
Current year-36.93%
1 week 1.12
Extreme 1.12
1.38
1 month 1.12
Extreme 1.12
1.82
Current year 1.12
Extreme 1.12
2.58
1 year 1.12
Extreme 1.12
2.58
3 years 1.1
Extreme 1.105
7.45
5 years 1.1
Extreme 1.105
7.45
10 years 1.1
Extreme 1.105
53.24
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 53 01/09/2014
Chief Executive Officer 61 01/03/2016
Director of Finance/CFO 56 07/08/2023
Director TitleAgeSince
Chairman 61 01/10/2014
Director/Board Member 78 01/08/2014
Director/Board Member 71 01/03/2018
Date Insider Type Main position Quantity % Market Cap. Importance
2/9/26 Sell

Executive/Senior Manager

-6,713 0.0025%
29/6/26 Free

Director

79,167 0.0477%
18/3/26 Other

Chief Executive Officer

6,917,877 4.1641%
Change 5-day change 1-year change 3-year change Capi.($)
-6.82%-9.06%-16.33%-65.71% 351M
-0.04%+1.46%+45.53%+134.81% 1,276B
+0.28%+1.63%+44.89%+90.23% 676B
+1.23%+0.12%+31.09%+112.91% 519B
+0.02%+2.79%+44.10%+69.76% 388B
-0.34%-1.87%+62.24%+44.00% 365B
-1.29%+0.94%+29.88%+58.29% 307B
+0.09%+0.99%+5.87%+37.72% 287B
+0.63%-2.21%+38.25%+75.45% 252B
-0.69%-2.71%+38.51%+126.56% 212B
Average -0.52%+1.43%+32.40%+68.40% 428B
Weighted average by Cap. +0.05%+2.51%+40.41%+95.57%

Financials

2026 *2027 *
Net sales 151M 136M 125M 113M 214M 14.12B 220M 1.5B 599M 7.56B 565M 553M 24.06B 193M 174M 161M 145M 275M 18.12B 282M 1.93B 768M 9.7B 725M 710M 30.88B
Net income -229M -207M -191M -173M -326M -21.49B -334M -2.29B -912M -11.51B -860M -842M -36.63B -196M -177M -163M -148M -279M -18.38B -286M -1.96B -780M -9.84B -736M -720M -31.33B
Net Debt -152M -137M -127M -115M -217M -14.29B -222M -1.52B -606M -7.65B -572M -560M -24.35B -75.11M -67.7M -62.55M -56.54M -107M -7.04B -110M -750M -299M -3.77B -282M -276M -12.01B
Projected Income Statement - Annual - Autolus Therapeutics plc
Logo Autolus Therapeutics plc
Autolus Therapeutics plc is a United Kingdom-based early commercial-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. The Company has an approved commercial product, AUCATZYL, for the treatment of adult patients with r/r B-ALL. Using a suite of proprietary and modular T cell programming technologies, it is also developing five programs in seven hematological and solid tumor indications and one autoimmune indication. It is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and attack and eliminate these cells. Its product pipeline includes obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting TRBC 1 and TRBC 2.
Employees
753
Date Price Change Volume
12/11/26 US$1.255 -4.92% 3,560,481
10/11/26 US$1.320 0.00% 7,349,481
09/11/26 US$1.320 +3.13% 4,488,979
06/11/26 US$1.280 +1.59% 1,204,146
05/11/26 US$1.260 -8.70% 3,132,627
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Autolus Therapeutics plc
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
1.320USD
Average target price
8.750USD
Spread / Average Target
+562.88%
  1. Stock Market
  2. Stocks
  3. AUTL Stock